A Phase II Study of Gemcitabine-docetaxel Chemotherapy With VEGFR Inhibitor (Apatinib) for Pulmonary Resectable Metastases of Osteosarcoma
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Rivoceranib (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- Acronyms PROACH
- 10 Mar 2019 Status changed from not yet recruiting to recruiting.
- 25 Feb 2019 Planned End Date changed from 1 May 2022 to 1 Sep 2022.
- 16 Feb 2019 Planned primary completion date changed from 1 Nov 2021 to 1 Apr 2022.